Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September. Removing the ...
Oct 2, 2023
0
4
A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ...
Sep 28, 2023
0
1
Chronic bowel inflammation is based on an excessive or misdirected inflammatory reaction. Experts assume that the immune system also reacts incorrectly to microorganisms in the intestine that do not cause an inflammatory ...
Sep 26, 2023
0
153
Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are carrying cancer-typical alterations.
Sep 21, 2023
0
15
Artemisinin-based combination therapies (ACTs) are the globally-accepted first-line treatments for malaria—a mosquito-borne disease caused by the Plasmodium falciparum parasite that annually kills around 600,000 people, ...
Sep 21, 2023
0
43
Today, HIV can be managed with medical treatment. However, despite 40 years of intensive research, scientists have not yet succeeded in finding a cure for the disease. People with HIV experience a flare-up of the virus only ...
Sep 18, 2023
1
46
Hospital staff spend a significant amount of time working to protect patients from acquiring infections while they are being cared for in the hospital. They employ various methods from hand hygiene to isolation rooms to rigorous ...
Sep 18, 2023
0
72
The psychedelic drug MDMA can reduce symptoms of post-traumatic stress disorder, researchers reported in a new study published Thursday.
Sep 17, 2023
0
14
A new study is adding to evidence that the party drug "ecstasy" can boost the benefits of talk therapy for people suffering from post-traumatic stress disorder (PTSD).
Sep 14, 2023
1
62
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Sep 14, 2023
0
66
